Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (501-510 of 627) with videos related to

Pageof 63
Sort By:
Stroke|April 19, 2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillationGraeme J Hankey, Susanna R Stevens, Jonathan P Piccini, et al.
International Journal of Cardiology|June 26, 2018
Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trialsChristoph B Olivier, Vandana Sundaram, Deepak L Bhatt, et al.
International Journal of Cardiology|February 21, 2012
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 yearsMark Y Chan, Jie-Lena Sun, L Kristin Newby, et al.
Journal of the American College of Cardiology|October 27, 2022
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and AlbuminuriaAshish Sarraju, George Bakris, Christopher P Cannon, et al.
International Journal of Cardiology|February 12, 2013
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudySean van Diepen, L Kristin Newby, Renato D Lopes, et al.
Coronary Artery Disease|February 28, 2013
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trialSergio Leonardi, Amanda Stebbins, Renato D Lopes, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
Journal of Clinical and Translational Science|September 25, 2023
The evolving role of data & safety monitoring boards for real-world clinical trialsBryan J Bunning, Haley Hedlin, Jonathan H Chen, et al.
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Circulation|March 10, 2016
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical TrialsKristian Kragholm, Sarah A Goldstein, Qinghong Yang, et al.
Pageof 63

Showing results (501-510 of 627) with videos related to

Sort By:
Pageof 63
Stroke|April 19, 2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillationGraeme J Hankey, Susanna R Stevens, Jonathan P Piccini, et al.
International Journal of Cardiology|June 26, 2018
Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trialsChristoph B Olivier, Vandana Sundaram, Deepak L Bhatt, et al.
International Journal of Cardiology|February 21, 2012
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 yearsMark Y Chan, Jie-Lena Sun, L Kristin Newby, et al.
Journal of the American College of Cardiology|October 27, 2022
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and AlbuminuriaAshish Sarraju, George Bakris, Christopher P Cannon, et al.
International Journal of Cardiology|February 12, 2013
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudySean van Diepen, L Kristin Newby, Renato D Lopes, et al.
Coronary Artery Disease|February 28, 2013
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trialSergio Leonardi, Amanda Stebbins, Renato D Lopes, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
Journal of Clinical and Translational Science|September 25, 2023
The evolving role of data & safety monitoring boards for real-world clinical trialsBryan J Bunning, Haley Hedlin, Jonathan H Chen, et al.
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Circulation|March 10, 2016
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical TrialsKristian Kragholm, Sarah A Goldstein, Qinghong Yang, et al.
Pageof 63